Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Kichul | - |
dc.contributor.author | Park, Sung-Hwan | - |
dc.contributor.author | Park, Won | - |
dc.contributor.author | Baek, Han Joo | - |
dc.contributor.author | Lee, Yun Jong | - |
dc.contributor.author | Kang, Seong Wook | - |
dc.contributor.author | Choe, Jung-Yoon | - |
dc.contributor.author | Yoo, Wan-Hee | - |
dc.contributor.author | Park, Yong-Beom | - |
dc.contributor.author | Song, Jung-Soo | - |
dc.contributor.author | Lee, Seung-Geun | - |
dc.contributor.author | Yoo, Bin | - |
dc.contributor.author | Yoo, Dae-Hyun | - |
dc.contributor.author | Song, Yeong Wook | - |
dc.date.available | 2020-02-27T19:43:57Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2017-02 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6427 | - |
dc.description.abstract | Purpose: Our aim was to investigate the efficacy of monthly oral ibandronate in Korean women with rheumatoid arthritis and reduced bone mineral density (BMD) receiving long-term glucocorticoids. Methods: Patients (n = 167 women) were randomly assigned (1:1) to receive ibandronate 150 mg or placebo every 4 weeks. Patients had taken glucocorticoid (equivalent of daily prednisolone >= 5 mg) for 3 or more consecutive months before enrollment, and had a lumbar spine 1 to 4 (L1L4) T-score of < -1.0 and >= -2.5. Both groups were provided with daily calcium carbonate and cholecalciferol. The primary end point was the L1 to L4 BMD percent changes at 48 weeks compared with baseline. Findings: Baseline characteristics were comparable between the 2 groups. BMD percent changes in L1 to L4 at 48 weeks were significantly different between the ibandronate versus the placebo group (+3.7% [5.1%] vs -1.9% [4.4%], respectively; P < 0.0001). BMD percent changes at 48 weeks in femur neck and total hip also had similar results (P = 0.0073 and P = 0.0031, respectively). Decrease of serum type 1 collagen C-terminal telopeptide was significant at both 24 and 48 weeks in the ibandronate group. There was no incident of fragility fracture in both groups during the study period. Safety profiles, including adverse events, were comparable between the 2 groups. (C) 2017 Elsevier HS Journals, Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.subject | CORTICOSTEROID-INDUCED OSTEOPOROSIS | - |
dc.subject | POSTMENOPAUSAL OSTEOPOROSIS | - |
dc.subject | MINERAL DENSITY | - |
dc.subject | VERTEBRAL FRACTURES | - |
dc.subject | PREVENTION | - |
dc.subject | THERAPY | - |
dc.subject | ALENDRONATE | - |
dc.subject | EFFICACY | - |
dc.subject | BISPHOSPHONATES | - |
dc.subject | RECOMMENDATIONS | - |
dc.title | Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000395850900006 | - |
dc.identifier.doi | 10.1016/j.clinthera.2017.01.008 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.39, no.2, pp.268 - 278 | - |
dc.identifier.scopusid | 2-s2.0-85011310501 | - |
dc.citation.endPage | 278 | - |
dc.citation.startPage | 268 | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 39 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Baek, Han Joo | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | bone mineral density | - |
dc.subject.keywordAuthor | corticosteroids | - |
dc.subject.keywordAuthor | rheumatoid arthritis | - |
dc.subject.keywordAuthor | osteoporosis | - |
dc.subject.keywordPlus | CORTICOSTEROID-INDUCED OSTEOPOROSIS | - |
dc.subject.keywordPlus | POSTMENOPAUSAL OSTEOPOROSIS | - |
dc.subject.keywordPlus | MINERAL DENSITY | - |
dc.subject.keywordPlus | VERTEBRAL FRACTURES | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ALENDRONATE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | BISPHOSPHONATES | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.